Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

Maria Teresa Petrucci; Paola Finsinger; Marta Chisini; Fabiana Gentilini

首页> 外文期刊>Patient Preference and Adherence >Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

【24h】

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

机译：皮下硼替佐米治疗多发性骨髓瘤：患者的益处

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract: The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.

机译：摘要：沙利度胺，来那度胺和硼替佐米等新型药物的使用大大改善了多发性骨髓瘤患者的预后。不幸的是，除了具有更大的生物活性之外，这些药物还具有更大的毒性。为了评估由硼替佐米的耐受性和抗骨髓瘤活性驱动的对患者生活质量的积极影响，我们分析了已发表的数据，这些数据涉及每周和/或皮下给药一次用于提高其耐受性的不同策略。

著录项

来源
《Patient Preference and Adherence》 |2014年第1期|共8页
作者
Maria Teresa Petrucci; Paola Finsinger; Marta Chisini; Fabiana Gentilini;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate. [J] . Yokoyama Akihiro, Kada Akiko, Saito Akiko M., Acta medica Okayama . 2019,第6期

机译：通常不适合移植的老年多发性骨髓瘤（MM）患者具有很高的死亡和中止治疗的风险，因此需要一种方案，该方案应采用能够平衡安全性，耐受性和疗效的新型药物。我们评估了在不适合移植的老年初诊MM患者中，硼替佐米-地塞米松和来那度胺-地塞米松在63天周期内的交替治疗。在第1、8、15和22天每周一次皮下注射硼替佐米1.3 mg / m2;在第36-56天每天口服来那度胺15 mg;在第1、8、15、22、36、43、50和57天，口服地塞米松20 mg，共6个周期。主要终点是总体缓解率。
2. Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits [J] . Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Patient Preference and Adherence . 2014,第1期

机译：皮下硼替佐米治疗多发性骨髓瘤：患者的益处
3. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study [J] . Noemi Horvath Leukemia and lymphoma . 2019,第9a10期

机译：在患有先前未经处理的多发性骨髓瘤患者的皮下硼胺基诱导和自体干细胞移植后皮下硼胺，沙利度胺和泼尼松龙固结的第3期研究：VCAT研究
4. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits [O] . Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, 2014

机译：皮下硼替佐米用于多发性骨髓瘤的治疗：患者的利益
7. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? [O] . Gozzetti, Alessandro, Candi, Veronica, Zuanelli Brambilla, Corrado, 2016

机译：在对皮下硼替佐米给药无反应后静脉注射（IV）硼替佐米可引起多发性骨髓瘤患者的短暂反应：是否有任何患者对静脉注射硼替佐米更敏感？

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

摘要

著录项

相似文献

相关主题

期刊订阅